Further research is needed, however, to validate the expression changes of the synaptic and/or myeloid targets controlled by miR-150-5p and let-7b-5p, and to see how well the miRNAs perform as biomarkers of cognitive impairment, also in relation to other proposed biomarkers for MS cognitive impairment, such as CSF Tau [79]. The gene discussed is MAPT; the disease is Cognitive impairment.